Gastrointestinal Cancer

Jonathan R. Strosberg, MD, discusses ongoing advances and challenges in the treatment of patients with NETs.

People with stage III colon cancer who regularly eat nuts are at significantly lower risk of cancer recurrence and mortality than those who don

Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, University of Chicago Medicine, discusses a study of margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) in gastroesophageal junction (GEJ) or gastric adenocarcinoma.

Michael J. Pishvaian, MD, discusses expanded testing for biomarkers, using liquid biopsies to predict response to treatment, and the importance of identifying increasingly specific subsets of GI cancers to make treatment decisions.

Allyson Ocean, MD, discusses the development of novel therapeutic regimens in pancreatic cancer.

Although the standard-of-care treatment for patients with liver metastases developing from colorectal cancer is liver resection, only one-third of these patients are candidates for surgery.

Aiwu Ruth He, MD, PhD, associate professor of medicine, Georgetown-Lombardi Comprehensive Cancer Center, discusses the future of precision medicine in gastrointestinal malignancies.

Michael A. Morse, MD, professor, Medicine, Department of Surgery, Duke University School of Medicine, Duke Cancer Institute, reflects on recent data in advanced colorectal cancer.